Document is current
Any future updates will be listed below
-
Authors
Hughes, Derralynn A. https://orcid.org/0000-0003-4531-9173
Aguiar, Patrício
Lidove, Olivier
Nicholls, Kathleen
Nowak, Albina
Thomas, Mark
Torra, Roser
Vujkovac, Bojan
West, Michael L.
Feriozzi, Sandro
-
Funding
Funding for this research was provided by:
Takeda Pharmaceutical Company (IME-GBR-15474)
- License Information
-
More Information
Article History
Received: 24 September 2021
Accepted: 16 January 2022
First Online: 8 February 2022
Declarations
:
: No patient-level data are reported in this study and no ethical approval was sought.
: Not applicable.
: DAH: advisory boards for Amicus Therapeutics, Sanofi, and Shire (now part of Takeda); consulting fees from Amicus Therapeutics, Idorsia Pharmaceuticals, Sanofi, and Shire (now part of Takeda); fees from Amicus Therapeutics, Sanofi, and Shire (now part of Takeda). PA: research grant and fees from Shire (now part of Takeda); fees from Amicus Therapeutics, BioMarin Pharmaceutical, Sanofi, and Ultragenyx Pharmaceutical. OL: travel grants and speaker fees from Amicus Therapeutics, Sanofi Genzyme, and Shire HGT. KN: research support and/or fees from Amicus Therapeutics, Idorsia Pharmaceuticals, Protalix Biotherapeutics, Sanofi, and Shire (now part of Takeda); advisory boards for Amicus Therapeutics, Sanofi, and Shire (now part of Takeda). AN: fees and research support from Amicus Therapeutics, Sanofi Genzyme, and Shire (now part of Takeda). MT: advisory boards for Amicus Therapeutics, Sanofi, and Shire (now part of Takeda); travel grants and speaker fees from Amicus Therapeutics, Sanofi, and Shire (now part of Takeda); research funding from 4D Molecular Therapeutics, Amicus Therapeutics, AVROBIO, and Idorsia Pharmaceuticals. RTB: travel grants, speaker fees, or consultation fees from Amicus, Sanofi Genzyme, and Takeda. BV: speaker fees and travel support from Greenovation, Sanofi Genzyme, and Shire (now part of Takeda); advisory board fees from Sanofi Genzyme. MLW: advisory boards for Amicus Therapeutics, Sanofi, and Shire (now part of Takeda); fees from Amicus Therapeutics, Sanofi, and Shire (now part of Takeda); research funding from Amicus Therapeutics, Idorisia Pharmaceuticals, Protalix Biotherapeutics, and Shire (now part of Takeda). SF: advisory boards for Amicus Therapeutics; consulting fees from Shire (now part of Takeda); contracted research from Shire (now part of Takeda); fees from Amicus Therapeutics, Sanofi, and Shire (now part of Takeda); speakers bureaux for Amicus Therapeutics, Sanofi, and Shire (now part of Takeda); travel expenses from Amicus, Sanofi and Shire (now part of Takeda).
